Details
Stereochemistry | MIXED |
Molecular Formula | C14H18N2O3 |
Molecular Weight | 262.3043 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 0 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC#CC(C)C1(CC=C)C(=O)NC(=O)N(C)C1=O
InChI
InChIKey=NZXKDOXHBHYTKP-UHFFFAOYSA-N
InChI=1S/C14H18N2O3/c1-5-7-8-10(3)14(9-6-2)11(17)15-13(19)16(4)12(14)18/h6,10H,2,5,9H2,1,3-4H3,(H,15,17,19)
Molecular Formula | C14H18N2O3 |
Molecular Weight | 262.3043 |
Charge | 0 |
Count |
|
Stereochemistry | MIXED |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Methohexital is an ultrashort-acting barbiturate widely used in dentistry because of its rapid onset, predictable effects, and short duration of action. It was marked under the name brevital sodium for the intravenous anaesthesia. It has also been commonly used to induce deep sedation. Like other barbiturates, methohexital exerts its effects through the gamma-aminobutyric acid (GABA) receptor complex. By binding to its own receptor on the complex, methohexital augments the inhibitory effect of GABA on neurons and additionally can exert a similar effect independent of GABA.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18568113
Curator's Comment: SM Chernish’s group at Lilly Research Laboratories (Indianapolis, USA) in 1956.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2093872 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1842156 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | BREVITAL SODIUM Approved UseBrevital Sodium can be used in adults as follows: For intravenous induction of anesthesia prior to the use of other general anesthetic agents. For intravenous induction of anesthesia and as an adjunct to subpotent inhalational anesthetic agents (such as nitrous oxide in oxygen) for short surgical procedures; Brevital Sodium may be given by infusion or intermittent injection. For use along with other parenteral agents, usually narcotic analgesics, to supplement subpotent inhalational anesthetic agents (such as nitrous oxide in oxygen) for longer surgical procedures. As intravenous anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli (see WARNINGS ). As an agent for inducing a hypnotic state. Brevital Sodium can be used in pediatric patients older than 1 month as follows: For rectal or intramuscular induction of anesthesia prior to the use of other general anesthetic agents. For rectal or intramuscular induction of anesthesia and as an adjunct to subpotent inhalational anesthetic agents for short surgical procedures. As rectal or intramuscular anesthesia for short surgical, diagnostic, or therapeutic procedures associated with minimal painful stimuli. Launch Date1960 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.8 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4005094 |
25 mg/kg single, rectal dose: 25 mg/kg route of administration: Rectal experiment type: SINGLE co-administered: |
METHOHEXITAL plasma | Homo sapiens population: HEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.39 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2024566 |
2 mg/kg single, intravenous dose: 2 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
METHOHEXITAL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
2.24 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2024566/ |
2 mg/kg single, intravenous dose: 2 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
METHOHEXITAL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2.71 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2024566/ |
2 mg/kg single, intravenous dose: 2 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
METHOHEXITAL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
151 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2024566 |
2 mg/kg single, intravenous dose: 2 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
METHOHEXITAL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
136 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2024566/ |
2 mg/kg single, intravenous dose: 2 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
METHOHEXITAL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
204 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2024566/ |
2 mg/kg single, intravenous dose: 2 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
METHOHEXITAL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
102 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4005094 |
25 mg/kg single, rectal dose: 25 mg/kg route of administration: Rectal experiment type: SINGLE co-administered: |
METHOHEXITAL plasma | Homo sapiens population: HEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
27.1% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17171861 |
1 % single, intravenous dose: 1 % route of administration: Intravenous experiment type: SINGLE co-administered: |
METHOHEXITAL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
30 mg/kg single, rectal Dose: 30 mg/kg Route: rectal Route: single Dose: 30 mg/kg Sources: |
unhealthy, 2.6 + 2.2 years n = 648 Health Status: unhealthy Age Group: 2.6 + 2.2 years Population Size: 648 Sources: |
Other AEs: Airways obstruction, Transient nocturnal oxygen desaturation... Other AEs: Airways obstruction (4%) Sources: Transient nocturnal oxygen desaturation (4%) |
2 mg/mL single, intravenous Dose: 2 mg/mL Route: intravenous Route: single Dose: 2 mg/mL Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Disc. AE: Seizures, Hepatic dysfunction NOS... AEs leading to discontinuation/dose reduction: Seizures Sources: Hepatic dysfunction NOS (severe) Instability cardiovascular (severe) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Airways obstruction | 4% | 30 mg/kg single, rectal Dose: 30 mg/kg Route: rectal Route: single Dose: 30 mg/kg Sources: |
unhealthy, 2.6 + 2.2 years n = 648 Health Status: unhealthy Age Group: 2.6 + 2.2 years Population Size: 648 Sources: |
Transient nocturnal oxygen desaturation | 4% | 30 mg/kg single, rectal Dose: 30 mg/kg Route: rectal Route: single Dose: 30 mg/kg Sources: |
unhealthy, 2.6 + 2.2 years n = 648 Health Status: unhealthy Age Group: 2.6 + 2.2 years Population Size: 648 Sources: |
Seizures | Disc. AE | 2 mg/mL single, intravenous Dose: 2 mg/mL Route: intravenous Route: single Dose: 2 mg/mL Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Hepatic dysfunction NOS | severe Disc. AE |
2 mg/mL single, intravenous Dose: 2 mg/mL Route: intravenous Route: single Dose: 2 mg/mL Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Instability cardiovascular | severe Disc. AE |
2 mg/mL single, intravenous Dose: 2 mg/mL Route: intravenous Route: single Dose: 2 mg/mL Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.preprints.org/manuscript/202101.0503/v1 Page: 3.0 |
likely | |||
Sources: https://www.preprints.org/manuscript/202101.0503/v1 Page: 3.0 |
likely | |||
Sources: https://www.preprints.org/manuscript/202101.0503/v1 Page: 3.0 |
likely | |||
yes | ||||
Page: 1643.0 |
yes | |||
Page: 891.0 |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 265.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Methohexitone and propanidid. A comparative investigation of the side effects. | 1969 Feb |
|
Activation of the electroencephalogram with intravenous Brietal (methohexitone): the findings in 100 cases. | 1971 Oct |
|
A rare allergic reaction to sodium methohexital. | 1972 Dec |
|
Intramuscular sodium methohexital as a sole pediatric anesthetic-analgesic agent. | 1972 Nov-Dec |
|
Seizure duration in unilateral electroconvulsive therapy. A comparison of the anaesthetic agents etomidate and Althesin with methohexitone. | 1984 Jun |
|
Clonidine and methohexital-induced epileptic magnetoencephalographic discharges in patients with focal epilepsies. | 1998 Aug |
|
Seizures during intracarotid methohexital and amobarbital testing. | 2007 Feb |
|
Transient global amnesia after ablation of premature ventricular beats arising from the right coronary cusp. | 2010 Aug 15 |
Patents
Sample Use Guides
Dosage is highly individualized: the drug should be administered only by those completely familiar with its quantitative differences from other barbiturate anesthetics. Adult: brevital sodium (METHOHEXITAL SODIUM) is administered intravenously in a concentration of no higher than 1%. Higher concentrations markedly increase the incidence of muscular movements and irregularities in respiration and blood pressure.
Induction of anesthesia: a 1% solution is administered at a rate of about 1 mL/5 seconds. Gaseous anesthetics and/or skeletal muscle relaxants may be administered concomitantly. The dose required for induction may range from 50 to 120 mg or more but averages about 70 mg. The usual dosage in adults ranges from 1 to 1.5 mg/kg. The induction dose usually provides anesthesia for 5 to 7 minutes. Maintenance of anesthesia: may be accomplished by intermittent injections of the 1% solution or, more easily, by continuous intravenous drip of a 0.2% solution. Intermittent injections of about 20 to 40 mg (2 to 4 mL of a 1% solution) may be given as required, usually every 4 to 7 minutes. For continuous drip, the average rate of administration is about 3 mL of a 0.2% solution/minute (1 drop/second). The rate of flow must be individualized for each patient. For longer surgical procedures, gradual reduction in the rate of administration is recommended
Pediatric Patients: Brevital Sodium is administered intramuscularly in a 5% concentration and administered rectally as a 1% solution.
Induction of anesthesia: by the intramuscular route of administration, the usual dose ranges from 6.6 to 10 mg/kg of the 5% concentration. For rectal administration, the usual dose for induction is 25 mg/kg using the 1% solution.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9732376
To explore the mechanism by which methohexital (MTH) activates epileptiform activity in patients with epilepsy, it was examined the effects of MTH on hippocampal CA1 and neocortical neurons via extracellular and whole-cell patch-clamp recordings in rat brain slices. Perfusion of slices with 10 to 100 microM MTH caused no significant change in glutamatergic transmission in the hippocampal CA1 region, but enhanced gamma-aminobutyric acid (GABA)A-mediated inhibitory postsynaptic currents and induced spontaneous inhibitory postsynaptic currents in neocortical and hippocampal CA1 neurons. In addition, MTH induced a tonic, bicuculline-sensitive hyperpolarization in association with increases in membrane conductance, suggesting a direct stimulation of GABAA receptors by MTH. Spontaneous epileptiform activity was not observed in the neocortex and hippocampus after exposure of slices to MTH, neither in the standard in vitro condition nor in the presence of 4-aminopyridine, which promotes rhythmic synaptic activities.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:12:00 GMT 2023
by
admin
on
Fri Dec 15 16:12:00 GMT 2023
|
Record UNII |
E5B8ND5IPE
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C67084
Created by
admin on Fri Dec 15 16:12:01 GMT 2023 , Edited by admin on Fri Dec 15 16:12:01 GMT 2023
|
||
|
WHO-ATC |
N01AF01
Created by
admin on Fri Dec 15 16:12:00 GMT 2023 , Edited by admin on Fri Dec 15 16:12:00 GMT 2023
|
||
|
WHO-VATC |
QN05CA15
Created by
admin on Fri Dec 15 16:12:01 GMT 2023 , Edited by admin on Fri Dec 15 16:12:01 GMT 2023
|
||
|
WHO-VATC |
QN01AF01
Created by
admin on Fri Dec 15 16:12:01 GMT 2023 , Edited by admin on Fri Dec 15 16:12:01 GMT 2023
|
||
|
NDF-RT |
N0000175693
Created by
admin on Fri Dec 15 16:12:01 GMT 2023 , Edited by admin on Fri Dec 15 16:12:01 GMT 2023
|
||
|
NDF-RT |
N0000008016
Created by
admin on Fri Dec 15 16:12:01 GMT 2023 , Edited by admin on Fri Dec 15 16:12:01 GMT 2023
|
||
|
DEA NO. |
2264
Created by
admin on Fri Dec 15 16:12:00 GMT 2023 , Edited by admin on Fri Dec 15 16:12:00 GMT 2023
|
||
|
WHO-ATC |
N05CA15
Created by
admin on Fri Dec 15 16:12:00 GMT 2023 , Edited by admin on Fri Dec 15 16:12:00 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
205-798-6
Created by
admin on Fri Dec 15 16:12:01 GMT 2023 , Edited by admin on Fri Dec 15 16:12:01 GMT 2023
|
PRIMARY | |||
|
1413000
Created by
admin on Fri Dec 15 16:12:01 GMT 2023 , Edited by admin on Fri Dec 15 16:12:01 GMT 2023
|
PRIMARY | |||
|
7233
Created by
admin on Fri Dec 15 16:12:01 GMT 2023 , Edited by admin on Fri Dec 15 16:12:01 GMT 2023
|
PRIMARY | |||
|
151-83-7
Created by
admin on Fri Dec 15 16:12:00 GMT 2023 , Edited by admin on Fri Dec 15 16:12:00 GMT 2023
|
PRIMARY | |||
|
100000088237
Created by
admin on Fri Dec 15 16:12:01 GMT 2023 , Edited by admin on Fri Dec 15 16:12:01 GMT 2023
|
PRIMARY | |||
|
1748
Created by
admin on Fri Dec 15 16:12:01 GMT 2023 , Edited by admin on Fri Dec 15 16:12:01 GMT 2023
|
PRIMARY | |||
|
METHOHEXITAL
Created by
admin on Fri Dec 15 16:12:01 GMT 2023 , Edited by admin on Fri Dec 15 16:12:01 GMT 2023
|
PRIMARY | |||
|
DB00474
Created by
admin on Fri Dec 15 16:12:01 GMT 2023 , Edited by admin on Fri Dec 15 16:12:01 GMT 2023
|
PRIMARY | |||
|
9034
Created by
admin on Fri Dec 15 16:12:01 GMT 2023 , Edited by admin on Fri Dec 15 16:12:01 GMT 2023
|
PRIMARY | |||
|
SUB14540MIG
Created by
admin on Fri Dec 15 16:12:00 GMT 2023 , Edited by admin on Fri Dec 15 16:12:00 GMT 2023
|
PRIMARY | |||
|
6847
Created by
admin on Fri Dec 15 16:12:01 GMT 2023 , Edited by admin on Fri Dec 15 16:12:01 GMT 2023
|
PRIMARY | RxNorm | ||
|
CHEMBL7413
Created by
admin on Fri Dec 15 16:12:00 GMT 2023 , Edited by admin on Fri Dec 15 16:12:00 GMT 2023
|
PRIMARY | |||
|
E5B8ND5IPE
Created by
admin on Fri Dec 15 16:12:00 GMT 2023 , Edited by admin on Fri Dec 15 16:12:00 GMT 2023
|
PRIMARY | |||
|
807
Created by
admin on Fri Dec 15 16:12:01 GMT 2023 , Edited by admin on Fri Dec 15 16:12:01 GMT 2023
|
PRIMARY | |||
|
Methohexital
Created by
admin on Fri Dec 15 16:12:01 GMT 2023 , Edited by admin on Fri Dec 15 16:12:01 GMT 2023
|
PRIMARY | |||
|
102216
Created by
admin on Fri Dec 15 16:12:00 GMT 2023 , Edited by admin on Fri Dec 15 16:12:00 GMT 2023
|
PRIMARY | |||
|
C66116
Created by
admin on Fri Dec 15 16:12:01 GMT 2023 , Edited by admin on Fri Dec 15 16:12:01 GMT 2023
|
PRIMARY | |||
|
m7323
Created by
admin on Fri Dec 15 16:12:01 GMT 2023 , Edited by admin on Fri Dec 15 16:12:01 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID1023287
Created by
admin on Fri Dec 15 16:12:01 GMT 2023 , Edited by admin on Fri Dec 15 16:12:01 GMT 2023
|
PRIMARY | |||
|
E5B8ND5IPE
Created by
admin on Fri Dec 15 16:12:01 GMT 2023 , Edited by admin on Fri Dec 15 16:12:01 GMT 2023
|
PRIMARY | |||
|
D008723
Created by
admin on Fri Dec 15 16:12:01 GMT 2023 , Edited by admin on Fri Dec 15 16:12:01 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |